ObjectiveTo investigate the efficacy of co-infusing cord blood (CB) as the third party cells on graft versus host disease (allo-GVHD) prophylaxis after unrelated or haploidentical donor allogeneic hematopoietic stem cell transplantation (allo-HSCT).MethodsFrom 2007 to 2011,41 patients receiving unrelated or haploidentical donor allo-HSCT were analyzed retrospectively.Twenty-five patients received one unit of HLA 4/6-6/6 matched CB one day before SCT as CB group,and median MNC dose was (1.64 ± 0.49) × 107/kg.Sixteen cases not receiving CB served as control group.All patients received antithymocyte globulin,cyclosporine,methotrexate,and mycophenolate mofetil as GVHD prophylaxis.The incidence and severity of aGVHD,and treatment-related mortality were compared between two groups.ResultsThe main clinical characteristics in both groups were comparable.The cumulative incidence of aGVHD in CB group and control group was 44.0％ versus 68.8％ respectively (x2 =2.403,P＞0.05).The cumulative incidence of grades Ⅲ to ⅣV aGVHD in CB group and control group was 16.0％ and 37.5％ respectively (x2 =2.445,P＞0.05).The 100-day treatment-related mortality in CB group and control group was 12.0％ and 12.5％ respectively (x2 =0.002,P＞0.05).ConclusionCord blood as the third party cells might reduce the incidence and severity of aGVHD in unrelated or haploidentical donor HSCT.The efficacy and the mechanism of this strategy need to be further explored by prospective randomized controlled trials.

BACKGROUNDCisplatin-based chemotherapy is the standard regimens in the treatment of advanced non-small cell lung cancer (NSCLC). The aim of this trial is to evaluate the efficacy and toxicity of paclitaxel or gemcitabine combined with cispltin for patients with advanced NSCLC.

METHODSSeventy-seven advanced NSCLC patients were randomly divided into 2 groups, 39 in TP group and 38 in GP group. TP group: paclitaxel 135 mg/m², on day 1; cisplatin 30 mg/m², on days 1-3. GP group: gemcitabine 1000 mg/m², on days 1, 8; cisplatin 30 mg/m², on days 1-3.

RESULTSPatients' characteristics were similar between the two groups. The overall response rate was 46.2% in the TP group and 42.1% in the GP group. There was no statistically significant difference in response rate between the two groups (P > 0.05). The major cytotoxicity was leukopenia in the TP group and thrombocytopenia in the GP group.

CONCLUSIONSBoth TP and GP regimens are effective for advanced NSCLC and have no significant difference. The side effects of the two regimens are different but all adverse reactions are tolerable.